The UCSF Experimental Cellular Therapy Group is composed of investigators at UCSF and affiliated institutions who develop new cellular therapy products and manufacture these products to support phase 1 clinical trials. We have expertise in every aspect of cellular therapy drug development from setting initial product specifications through manufacturing for clinical trials. We develop and implement new approaches and technologies to improve the efficiency and safety of cellular therapy development. There are many opportunities for training. The group is coordinated by Dr. Jonathan Esensten, Assistant Adjunct Professor in the Department of Laboratory Medicine. For inquiries, please email [email protected]
Principle investigators and sponsoring institutions for current cellular therapy projects:
Jeffrey Bluestone, PhD, UCSF Qizhi Tang, PhD, UCSF |
Regulatory T cell therapies |
Alexander Marson MD, PhD, UCSF Innovative Genomics Institute UCSF Living Therapeutics Initiative |
CRISPR/Cas9 gene modified T cell therapies |
Hideho Okada, MD, PhD, UCSF Wendell Lim, PhD, UCSF Lisa Butterfied, PhD, Parker Institute for Cancer Immunotherapy |
T cell therapy for glioblastoma |
Justin Eyeqem, PhD, UCSF Alexander Marson MD, PhD UCSF TomMar, MD, UCSF Brian Shy MD, PhD UCSF |
CAR T therapy for multiple myeloma |